HEALTH TECHNOLOGY

Tecsys Bolsters Its Industry Leading End-to-End Elite™ Healthcare Supply Chain Execution Platform with Consolidated Pharmacy Inventory Management

Tecsys | August 24, 2021

Tecsys Inc. (TSX: TCS), an industry-leading supply chain management software company, today announces another significant milestone to its end-to-end Elite™ Healthcare supply chain execution platform with its end-to-end consolidated pharmacy inventory management solution. Integrating unified visibility and control from the point of reception to the point of use, Tecsys' consolidated pharmacy inventory management solution extends its best-in-class consolidated service center model to pharmaceutical supplies, lending the same sophisticated warehouse, distribution and point of use orchestration software to pharmacy operations.


"As healthcare supply chain continues to move from functional to strategic, it becomes irreconcilable to operate different legs of the supply chain with patchwork solutions that don't speak to each other," explains Chris Jellison, vice president, Pharmacy at Parkview Health.


Tecsys' consolidated pharmacy inventory management solution enables centralized strategic buying, management of pharmaceutical spend and procurement operations. By employing consolidated service center supply chain practices, the software helps to manage and mitigate drug shortages, reduces inventory and waste, and streamlines operations, all while integrating regulated processes to remain DSCSA compliant and optimize 340B programs.


"We already have multiple U.S. health systems who have selected this Tecsys platform, and several more looking to extend supply chain's reach and responsibility into pharmacy," says Peter Brereton, president and CEO at Tecsys. "For years, our customers have been honing their supply chains to ensure front-line healthcare workers are armed to deliver care that is both clinically and financially responsible, and this extension is a savvy step toward holistic management of goods within a health system. If we are serious about trying to root out blind spots in the hospital supply chain, pharmaceutical supplies is an area that stands to bridge those data gaps from an analytics and optimization lens."


The pharmaceutical supply chain typically operates in parallel to medical supply management, running siloed processes to track consumption and traceability as well as manage procurement and demand planning. To address this disconnect, progressive health systems are leveraging their Tecsys-enabled consolidated service centers (CSCs) to centralize pharmacy operations and consolidate supply chain management strategies. Tecsys software is able to reconcile these discrete datasets and procurement strategies under a common platform, providing centralized control and management of all supply chain execution supplies. Consolidated management of a pharmacy's supply chain allows for cost per case and cost per procedure analyses by factoring in pharmaceutical supplies, helping hospitals to optimize reimbursement programs and enable more strategic sourcing.


"Over the last decade, progressive health systems across the U.S. have adopted the CSC model to eliminate waste, streamline processes and tap into economies of scale," says Cory Turner, senior director, Healthcare Strategy. "Bringing pharmacy into that equation means extending much needed control and coordination to an historically bifurcated and disorganized inventory management operation. By applying the same sophistication to pharmacy as medical supplies, health systems are not only able to better orchestrate and analyze their operations, but they also stand to gain financial and clinical benefits as well."


Tecsys' consolidated pharmacy inventory management solution is embedded within the broader Tecsys Elite™ Healthcare portfolio, which combines for the most comprehensive supply chain execution system designed specifically for the healthcare industry. Optimized for the regulatory and operational complexities involved in orchestrating multiple clinical areas with differentiated clinical demands, the system provides unified visibility and control from the point of reception to the point of use.


About Tecsys
Tecsys is a global provider of supply chain solutions that equip the borderless enterprise for growth. Organizations thrive when they have the software, technology and expertise to drive operational greatness and deliver on their brand promise. Spanning healthcare, retail, service parts, third-party logistics, and general wholesale high-volume distribution industries, Tecsys delivers dynamic and powerful solutions for warehouse management, distribution and transportation management, supply management at point of use, retail order management, as well as complete financial management and analytics solutions. Tecsys' shares are listed on the Toronto Stock Exchange under the ticker symbol TCS.

Spotlight

Reva Technologies, a prominent healthcare and medical app development firm, is at the forefront of this healthcare uprising by providing high-end telemedicine app development solutions that help healthcare businesses improve diagnoses, streamline medical process flows, and improve patient care.

Spotlight

Reva Technologies, a prominent healthcare and medical app development firm, is at the forefront of this healthcare uprising by providing high-end telemedicine app development solutions that help healthcare businesses improve diagnoses, streamline medical process flows, and improve patient care.

Related News

HEALTH TECHNOLOGY

Perimeter Medical Imaging AI Announces Commercial Placement of Perimeter S-Series OCT within National Healthcare Provider System

Perimeter Medical Imaging AI, Inc. | September 30, 2022

Perimeter Medical Imaging AI, Inc. announced the commercial placement of its flagship Perimeter S-Series OCT system at a hospital that is part of a major national healthcare system and one of the largest healthcare networks in North Texas. Perimeter is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs. “This commercial placement of our Perimeter S-Series OCT system at a hospital in a major healthcare network marks a significant milestone for us as we gain traction validating our commercial model. Perimeter S-Series OCT aims to improve patient outcomes and lower healthcare costs, and we are excited that leading surgeons and hospitals are seeing the potential of our ground-breaking technology.” Jeremy Sobotta, Perimeter’s Chief Executive Officer About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level, with 10x greater image resolution than X-ray and ultrasound, and 100x greater than MRI. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company’s ticker symbol “PINK” is a reference to the pink ribbons displayed during Breast Cancer Awareness Month.

Read More

HEALTHTECH SECURITY

KORU Medical Systems Appoints Brent Rutland as Vice President of Medical Affairs

KORU Medical | October 13, 2022

KORU Medical Systems, Inc. a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions announced the appointment of Brent Rutland as the Company’s new Vice President of Medical Affairs. Mr. Rutland will provide leadership in the Company’s clinical and data generation strategies, key opinion leader engagement, assessing new subcutaneous drug candidates for use with the Company’s products and overseeing the medical affairs team. Additionally, Mr. Rutland will be the clinical resource for the Company’s efforts in regulatory submissions, failure modes and effects analysis, health hazard evaluations, human factors design, new product development and clinical evaluation updates. “We are excited to bring Brent’s competence to the organization – his background was a perfect fit. His expertise will advance clinical evidence generation in support of our product pipeline, provide valuable insight to our drug therapy candidates and help develop important key opinion leader relationships. Brent has helped build multiple data and clinical strategies, internal teams, and external networks in his past. His deep industry experience and passion for the patient, will make him an impactful contributor to the Company’s strategy.” Linda Tharby, President and CEO Mr. Rutland’s career history spans an impressive 27 years and includes working with Baxter Healthcare as a Senior Medical Science Liaison and most recently with La Jolla Pharmaceutical Company as a Senior Director, Health Outcomes. During his career he helped launch 7 vaccines, 4 drugs and 1 device. Most notably, Brent aided Baxter in the launch of Hylenex for SQ rehydration where he also helped build the Medical Affairs department. He has received several awards throughout his career, with the most recent being the President’s Circle Award for Medical Affairs at La Jolla. Brent holds a Bachelor of Science degree from Texas A&M University, an MBA in Global Management from the University of Houston, and his Master of Public Health from the University of North Carolina in Epidemiology. “I was immediately drawn to the opportunity to work at KORU Medical as I saw the potential for future growth supported by building out the medical science and the team,” said Brent Rutland, Vice President of Medical Affairs. “Medical affairs helps fulfill the unmet needs of the patient through the generation and delivery of scientific evidence to various key outside stakeholders. I look forward to developing a collaborative strategy to support the Company’s overall goals.” About KORU Medical KORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System. currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings.

Read More

HEALTH TECHNOLOGY

Biobeat joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

Biobeat | September 07, 2022

Biobeat, a company focused on remote patient monitoring platforms with artificial intelligence analysis capability, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. The Innovators' Network is a consortium that connects entrepreneurs, providers, researchers and payers. Innovators' Network members also have access to the Association's digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers. "The Center aims to advance the rapid, efficient, and effective development of healthcare technology," said Robert A. Harrington, M.D., FAHA, past president of the American Heart Association (2019-2020), volunteer chair of the American Heart Association's Health Tech Advisory Group for the Center and Arthur L. Bloomfield professor and chair department of medicine, Stanford University. "Joining the Innovators' Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena." "Biobeat is excited to join the Innovators' Network. It will provide unique access to the Association's research and others innovating in this space, helping us to achieve our goals of improving cardiovascular health and helping health care providers." Arik Eisenkraft, MD, VP Clinical and Regulation at Biobeat About Biobeat Biobeat joins the Innovators' Network bringing with them the Biobeat solution, the first cuffless blood pressure measurement tool to receive FDA clearance. Biobeat leverages health-related artificial intelligence and med-tech capabilities to collect and analyze patient data with a suite of optical-based sensor monitors and machine learning data platforms focused on actionable insights. Wireless sensors worn on the wrist or chest allow remote patient monitoring for blood pressure and multiple physiological parameters. Patient health data is viewed by participating medical staff via Biobeat's secure HIPAA and GDPR compliant cloud-based patient management platform. The platform includes an automated real-time early warning score system that incorporates advanced artificial intelligence algorithms to provide alerts on patient health status. These capabilities are centered on supporting medical teams in providing tailored patient care such as adjustment of therapeutics and early prevention of specific disease exacerbations. The company anticipates that compliance with easy-to-wear cuffless health sensor solutions will help healthcare professionals engage in timely, proactive care for hypertension patients.

Read More